Tags

Type your tag names separated by a space and hit enter

A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review.
Life (Basel). 2020 Aug 09; 10(8)L

Abstract

Background: The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related disease (COVID-19) has rapidly spread to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Nowadays, one of the critical issues still to be pointed out regards COVID-19 treatment regimens and timing: which drug, in which phase, for how long? Methods: Our narrative review, developed using MEDLINE and EMBASE, summarizes the main evidences in favor or against the current proposed treatment regimens for COVID-19, with a particular focus on antiviral agents. Results: Although many agents have been proposed as possible treatment, to date, any of the potential drugs against SARS-CoV-2 has shown to be safe and effective for treating COVID-19. Despite the lack of definitive evidence, remdesivir remains the only antiviral with encouraging effects in hospitalized patients with COVID-19. Conclusions: In such a complex moment of global health emergency, it is hard to demand scientific evidence. Nevertheless, randomized clinical trials aiming to identify effective and safe drugs against SARS-CoV-2 infection are urgently needed in order to confirm or reject the currently available evidence.

Links

Authors+Show Affiliations

Department of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Department of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Department of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Department of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Department of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Vanvitelli Covid-Group

Department of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Pub Type(s)

Journal Article

Review

Language

eng

PubMed ID

32784922

Citation

Monari, Caterina, et al. "A Focus On the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): a Narrative Review." Life (Basel, Switzerland), vol. 10, no. 8, 2020.

Monari C, Gentile V, Camaioni C, et al. A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. Life (Basel). 2020;10(8).

Monari, C., Gentile, V., Camaioni, C., Marino, G., Coppola, N., & Vanvitelli Covid-Group, . (2020). A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. Life (Basel, Switzerland), 10(8). https://doi.org/10.3390/life10080146

Monari C, et al. A Focus On the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): a Narrative Review. Life (Basel). 2020 Aug 9;10(8) PubMed PMID: 32784922.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. AU - Monari,Caterina, AU - Gentile,Valeria, AU - Camaioni,Clarissa, AU - Marino,Giulia, AU - Coppola,Nicola, AU - Vanvitelli Covid-Group,, Y1 - 2020/08/09/ PY - 2020/07/05/received PY - 2020/08/05/revised PY - 2020/08/06/accepted PY - 2020/8/14/entrez PY - 2020/8/14/pubmed PY - 2020/8/14/medline KW - COVID-19 KW - antiviral therapy KW - current evidences KW - current recommendations KW - early phase KW - management JF - Life (Basel, Switzerland) JO - Life (Basel) VL - 10 IS - 8 N2 - Background: The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related disease (COVID-19) has rapidly spread to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Nowadays, one of the critical issues still to be pointed out regards COVID-19 treatment regimens and timing: which drug, in which phase, for how long? Methods: Our narrative review, developed using MEDLINE and EMBASE, summarizes the main evidences in favor or against the current proposed treatment regimens for COVID-19, with a particular focus on antiviral agents. Results: Although many agents have been proposed as possible treatment, to date, any of the potential drugs against SARS-CoV-2 has shown to be safe and effective for treating COVID-19. Despite the lack of definitive evidence, remdesivir remains the only antiviral with encouraging effects in hospitalized patients with COVID-19. Conclusions: In such a complex moment of global health emergency, it is hard to demand scientific evidence. Nevertheless, randomized clinical trials aiming to identify effective and safe drugs against SARS-CoV-2 infection are urgently needed in order to confirm or reject the currently available evidence. SN - 2075-1729 UR - https://www.unboundmedicine.com/medline/citation/32784922/A_Focus_on_the_Nowadays_Potential_Antiviral_Strategies_in_Early_Phase_of_Coronavirus_Disease_2019__Covid_19_:_A_Narrative_Review_ DB - PRIME DP - Unbound Medicine ER -